Optimisation of dose level and vaccination schedule for the VLA15 Lyme borreliosis vaccine candidate among healthy adults: two randomised, observer-blind, placebo-controlled, multicentre, phase 2 studies
- 31 May 2024
- journal article
- research article
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 24 (9) , 1045-1058
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Safety and immunogenicity of a novel multivalent OspA-based vaccine candidate against Lyme borreliosis: a randomised, phase 1 study in healthy adultsThe Lancet Infectious Diseases, 2023
- A brief history of OspA vaccines including their impact on diagnostic testing for Lyme diseaseDiagnostic Microbiology and Infectious Disease, 2022
- Clinical spectrum of Lyme diseaseEuropean Journal of Clinical Microbiology & Infectious Diseases, 2018
- Characterization and optimization of a novel vaccine for protection against Lyme borreliosisVaccine, 2015
- Utility of serodiagnostics designed for use in the United States for detection of Lyme borreliosis acquired in Europe and vice versaMedical Microbiology and Immunology, 2013
- Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trialThe Lancet Infectious Diseases, 2013
- Structure-based Design of a Second-generation Lyme Disease Vaccine Based on a C-terminal Fragment of Borrelia burgdorferi OspAJournal of Molecular Biology, 2005
- An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T cell epitopeProceedings of the National Academy of Sciences, 2004
- A Vaccine Consisting of RecombinantBorrelia burgdorferiOuter-Surface Protein A to Prevent Lyme DiseaseNew England Journal of Medicine, 1998
- Vaccination against Lyme Disease with RecombinantBorrelia burgdorferiOuter-Surface Lipoprotein A with AdjuvantNew England Journal of Medicine, 1998